Company
Envisagenics
From RNA Insight to Therapeutic Impact
- Status
- Operatingas of 2026-09-18
- Business model
- B2B
- Founded
- 2014
- envisagenics.com (opens in a new tab)
- LinkedIn (opens in a new tab)
- Press page (opens in a new tab)
- Careers (opens in a new tab)
Claim, correct or request removal
Record updated 28 September 2026
About
We discover novel, prevalent, and disease-specific drug targets through AI-driven analysis of RNA splicing. Our team combines deep expertise in RNA biology and AI to advance transformative treatments in immuno-oncology and RNA-targeted treatments for neurodegenerative diseases.
Funding snapshot
- Total raised
- $21.7MSEC form D sum, as of 2026-09-28Source (opens in a new tab)
- Latest round
- Series B2024-06-04
Funding rounds
- Series B
- 2024-06-04
- Series A
- 2021-09-29
- Round, 2021
- $19.2M2021-09-22, SEC form D sold, 24 investors
- Seed
- $2.4M2017-11-28, Company stated
- Round, 2017
- $2.5M2017-03-16, SEC form D sold, 6 investors
Products
- Other
- SpliceCore®
Loading relationship preview